Novel inhibitors in development for hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Novel inhibitors in development for hepatocellular carcinoma.

Novel inhibitors in development for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37725994

about

Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Latest developments in targeted therapy for hepatocellular carcinoma.AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.HCC therapies--lessons learned.Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survival.TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis.FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.

P2860

Q35641898-E7EE574B-77ED-4A2E-8B28-13AFB17B33D4 Q35872080-90120869-349E-4F97-B277-E7D09D5F8295 Q36729450-D4A0E97B-A0EA-4AE5-9C44-1A7C9B9C7BF7 Q37799829-99F3F35F-9F2F-44FA-81F5-C5DC80844632 Q37943905-824B22B5-3618-4C54-A5E4-A37D3E844E78 Q38184833-032740E8-2A8F-4A4A-A1A8-DEBFB7E1FBDB Q38610677-5F970F06-F132-405C-B12C-9E979870D389 Q39342887-FBD95783-7BE0-4580-9999-59C1308B39AE Q39486061-1DAFD6A5-F363-4FE1-95C0-FAC4753AFAFE Q39499156-FF20075E-9F92-44A4-948D-5B9DABD4AD44 Q39524844-E15C9A76-C6D2-414D-838E-0752B66F30B7 Q42362014-30276E1E-C274-4A6A-8B72-7833BC4E3D21 Q42745858-6FF1798C-3AAD-4B06-BF9F-F5932590DEEB Q43203316-F3E09B3D-6BED-43BE-96DC-4AB0CB458A19

P2860

Novel inhibitors in development for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37725994

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel inhibitors in development for hepatocellular carcinoma.

@en

Novel inhibitors in development for hepatocellular carcinoma.

@nl

type

label

Novel inhibitors in development for hepatocellular carcinoma.

@en

Novel inhibitors in development for hepatocellular carcinoma.

@nl

prefLabel

Novel inhibitors in development for hepatocellular carcinoma.

@en

Novel inhibitors in development for hepatocellular carcinoma.

@nl

P1433

Q37725994-E913FB3C-DEEE-47EC-80BA-9FC9434E5E47

P1476

Q37725994-FE1C4C6E-0C6D-4B13-8367-5496E5206F0C

P2093

Q37725994-92F3CA97-3CDB-4170-B73A-0F2D185A5535

Q37725994-BAE2F3B9-9FC6-4328-86C0-C49CD3783948

P2860

Q37725994-0877198F-916B-4978-8BBA-68277EFC80A1

Q37725994-0AF56712-5864-4CE0-B0F3-A73F338C2130

Q37725994-10290D7A-E2C7-45A4-8D40-6249204D5DF6

Q37725994-141B7C11-1F3E-475F-A6F7-73F9B007F8C0

Q37725994-19B9E46E-477F-4125-948F-B3403C09BB2A

Q37725994-1A9B55EA-535F-4942-80AE-5B5A5766774E

Q37725994-1B67DEB8-027D-4FA2-B62B-F98DD46E6E01

Q37725994-1C441C29-8167-43D6-BAAE-AB685B79BF23

Q37725994-21F7EFC0-BD53-4534-9A6A-FC4FDB92FF58

Q37725994-2EE9E8A5-0959-4AC7-BB74-925A4571D24B

P304

Q37725994-E130A9D1-8FF1-4305-9D12-E4E59D9FADFE

P31

Q37725994-9543FC26-97E9-4E5F-897D-FA04B251177C

P356

Q37725994-6428EE02-B77F-4775-B273-61E2961DC23D

P407

Q37725994-88889E78-D341-4754-9264-CA5836C46426

P433

Q37725994-AF29FA21-7307-4497-9C78-7FD0BF23CE5F

P478

Q37725994-77E3B3AA-7D62-41F1-A3DB-DBE05670320E

P577

Q37725994-2213F3B6-BFB9-49D1-BE8A-446D7ACDE1BB

P698

Q37725994-25C8FF73-0427-4D9A-BF4B-6BBEF0D91DBC

P356

13543781003767418

P1433

Expert Opinion on Investigational Drugs

P1476

Novel inhibitors in development for hepatocellular carcinoma.

@en

P2093

Marcus Alexander Wörns

http://www.w3.org/2001/XMLSchema#string

Peter Robert Galle

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Global cancer statistics, 2002

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor rec

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

P304

615-629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543781003767418

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20374038

http://www.w3.org/2001/XMLSchema#string